authority is contingent on Respondent being a practitioner with a valid DEA registration, see 21 U.S.C. 823(g)(2)(A); 21 CFR 1301.28(a), I will revoke his DATA-Waiver authority as well.

Order

Pursuant to the authority vested in me by 21 U.S.C. 823(f) and 824(a), as well as 28 CFR 0.100(b), I order that DEA Certificate of Registration No. BZ5641419 and DATA-Waiver Identification Number XZ5641419, issued to Witold Marek Zajewski, M.D., be, and they hereby are, revoked. I further order that any pending application of Witold Marek Zajewski to renew or modify the above registration, or any pending application of Witold Marek Zajewski for any other registration in the State of Illinois, be, and it hereby is, denied. This Order is effective immediately.¹


Robert W. Patterson,
Acting Administrator.

[FR Doc. 2018-07454 Filed 4–10–18; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances Registration

ACTION: Notice of registration.

<table>
<thead>
<tr>
<th>Company</th>
<th>FR docket</th>
<th>Published</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sharp (Bethlehem), LLC</td>
<td>83 FR 539</td>
<td>January 4, 2018.</td>
</tr>
<tr>
<td>Mylan Pharmaceuticals, Inc</td>
<td>83 FR 5809</td>
<td>February 9, 2018.</td>
</tr>
<tr>
<td>Meridian Medical Technologies, Inc</td>
<td>83 FR 5810</td>
<td>February 9, 2018.</td>
</tr>
<tr>
<td>Noramco, Inc</td>
<td>83 FR 5811</td>
<td>February 9, 2018.</td>
</tr>
<tr>
<td>Johnson Matthey, Inc</td>
<td>83 FR 5811</td>
<td>February 9, 2018.</td>
</tr>
</tbody>
</table>

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each company’s maintenance of effective controls against diversion by inspecting and testing each company’s physical security systems, verifying each company’s compliance with state and local laws, and reviewing each company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or II controlled substances to the above listed companies.


Susan A. Gibson,
Deputy Assistant Administrator.

[FR Doc. 2018–07444 Filed 4–10–18; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]

Bulk Manufacturer of Controlled Substances Registration

ACTION: Notice of registration.

<table>
<thead>
<tr>
<th>Company</th>
<th>FR docket</th>
<th>Published</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nanosyn, Inc</td>
<td>82 FR 56993</td>
<td>December 1, 2017.</td>
</tr>
<tr>
<td>Cambrex High Point, Inc</td>
<td>82 FR 61795</td>
<td>December 29, 2017.</td>
</tr>
<tr>
<td>AMPAC Fine Chemicals LLC</td>
<td>82 FR 61795</td>
<td>December 29, 2017.</td>
</tr>
</tbody>
</table>

¹ For the same reasons which led the IDFPR to revoke Respondent’s controlled substance license, I conclude that the public interest necessitates that this Order be effective immediately. 21 CFR 1316.67.
The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of these registrants to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each of the company’s maintenance of effective controls against diversion by inspecting and testing each company’s physical security systems, verifying each company’s compliance with state and local laws, and reviewing each company’s background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed companies.

Susan A. Gibson,
Deputy Assistant Administrator.

DEPARTMENT OF JUSTICE
Drug Enforcement Administration

[DOCKET NO. DEA–392]

Import of Controlled Substances Application: Almac Clinical Services Incorp (ACSI)

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before May 11, 2018. Such persons may also file a written request for a hearing on the application on or before May 11, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

DEPARTMENT OF JUSTICE

Agency Information Collection Activities: Proposed eCollection eComments Requested; Revision of a Currently Approved Collection; Comments Requested: National Crime Victimization Survey (NCVS)

AGENCY: Bureau of Justice Statistics, Department of Justice.

ACTION: 30-day notice.

SUMMARY: The Department of Justice (DOJ), Office of Justice Programs, Bureau of Justice Statistics, will be submitting a request to the Office of Management and Budget (OMB) for review and approval of a revision to the National Crime Victimization Survey information collection in accordance with the Paperwork Reduction Act of 1995. The proposed information collection, which is currently under OMB review, was previously published in the Federal Register on Monday, March 19, 2018, allowing a 30-day comment period. The requested revision impacts the minimum age at which respondents will be administered questions on their sexual orientation and gender identity, raising the minimum age from 16 to 18. This revision, which will be implemented within 6 months of OMB approval, will not impact the burden hours associated with the previous 30-day request.

DATES: Comments are encouraged and will be accepted for 30 days only until May 11, 2018.

FOR FURTHER INFORMATION CONTACT: If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Jennifer Truman, Statistician, Bureau of Justice Statistics, 810 Seventh Street NW, Washington, DC 20531 (email: Jennifer.Truman@ojp.usdoj.gov; telephone: 202–514–5083).

SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

—Evaluate the impact of the change on the functioning of the Bureau of Justice Statistics;
—Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information,